-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎ WuXi AppTec content team editor On October 12, 2021, Corium announced that the US FDA has set the new drug application (NDA) PDUFA target date for its donepezil (donepezil) transdermal patch Adlarity as March 11, 2022.
For the treatment of patients with dementia caused by mild/moderate/severe Alzheimer's disease
.
According to statistics from the World Health Organization, more than 55 million people worldwide suffer from dementia, and Alzheimer's disease accounts for approximately 60%-70% of these patients
.
Alzheimer's disease is a progressive and irreversible neurodegenerative disease, and currently there is no cure
.
It can cause changes in brain tissue, including abnormal accumulation of protein and loss of neuronal function, resulting in loss of memory, reasoning and thinking ability
.
Donepezil is a common cholinesterase inhibitor (cholinesterase inhibitors)
.
The US FDA previously approved donepezil as a once-daily oral tablet for the treatment of patients with mild/moderate/severe Alzheimer's disease
.
Image source: 123RFAdlarity is a transdermal preparation of donepezil, made using Corium's proprietary Corplex technology platform
.
Adlarity transdermal patches can be applied continuously for 7 days and have consistent adhesion
.
This method of administration avoids the inconvenience caused by daily oral administration for patients with obvious memory problems
.
With the slow and stable release of donepezil, the Adlarity transdermal system can regularly deliver the drug through the skin.
This design also avoids gastrointestinal absorption and related side effects
.
Corium is seeking to approve two Adlarity doses for transdermal delivery, each delivering 5 or 10 mg of donepezil daily
.
"Corium uses our innovative Corplex technology to improve the most commonly used first-line treatment for Alzheimer's disease patients," said Mr.
Perry J.
Sternberg, President and CEO of Corium.
"Our team at Corium is committed to developing innovative drugs.
To address the unmet treatment needs of people affected by Alzheimer’s disease and other central nervous system (CNS) diseases
.
"Reference: [1] Corium Receives March 11, 2022 PDUFA Date for New Drug Application for Adlarity® Patch (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease.
Retrieved October 12, 2021, from https:// new-drug-application-for-Adlarity-patch-donepezil-transdermal-system-for-treatment-of-patients-with-alzheimers-disease-301397264.
htmlDisclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research Progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
For the treatment of patients with dementia caused by mild/moderate/severe Alzheimer's disease
.
According to statistics from the World Health Organization, more than 55 million people worldwide suffer from dementia, and Alzheimer's disease accounts for approximately 60%-70% of these patients
.
Alzheimer's disease is a progressive and irreversible neurodegenerative disease, and currently there is no cure
.
It can cause changes in brain tissue, including abnormal accumulation of protein and loss of neuronal function, resulting in loss of memory, reasoning and thinking ability
.
Donepezil is a common cholinesterase inhibitor (cholinesterase inhibitors)
.
The US FDA previously approved donepezil as a once-daily oral tablet for the treatment of patients with mild/moderate/severe Alzheimer's disease
.
Image source: 123RFAdlarity is a transdermal preparation of donepezil, made using Corium's proprietary Corplex technology platform
.
Adlarity transdermal patches can be applied continuously for 7 days and have consistent adhesion
.
This method of administration avoids the inconvenience caused by daily oral administration for patients with obvious memory problems
.
With the slow and stable release of donepezil, the Adlarity transdermal system can regularly deliver the drug through the skin.
This design also avoids gastrointestinal absorption and related side effects
.
Corium is seeking to approve two Adlarity doses for transdermal delivery, each delivering 5 or 10 mg of donepezil daily
.
"Corium uses our innovative Corplex technology to improve the most commonly used first-line treatment for Alzheimer's disease patients," said Mr.
Perry J.
Sternberg, President and CEO of Corium.
"Our team at Corium is committed to developing innovative drugs.
To address the unmet treatment needs of people affected by Alzheimer’s disease and other central nervous system (CNS) diseases
.
"Reference: [1] Corium Receives March 11, 2022 PDUFA Date for New Drug Application for Adlarity® Patch (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease.
Retrieved October 12, 2021, from https:// new-drug-application-for-Adlarity-patch-donepezil-transdermal-system-for-treatment-of-patients-with-alzheimers-disease-301397264.
htmlDisclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research Progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
